Please Wait
Applying Filters...
menu
    • menu
    Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

    Stock Recap
    #PipelineProspector

    Menu

    MK-869, L-754030, Emend, Aprepitant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 11,167Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    29/11/2025 Inke S.A
    Spain
    		 Inke, S.A. Castellbisbal ES CEP 2022-247 - Rev 00 Aprepitant, Micronised and non micronised 2024-10-29 Valid Chemical 2757
    29/11/2025 Sichuan Qingmu Pharmaceutical
    China
    		 CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Chengdu CN CEP 2021-323 - Rev 00 Aprepitant 2024-01-22 Valid Chemical 2757